Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
38 hedge funds and large institutions have $292M invested in Paratek Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
3% more funds holding
Funds holding: 37 → 38 (+1)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
15% less capital invested
Capital invested by funds: $345M → $292M (-$52.5M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$6.24M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.47M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$2.17M |
| 4 |
GAI
General American Investors
New York
|
+$1.91M |
| 5 |
Bank of New York Mellon
New York
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$3.79M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.08M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.04M |
| 4 |
SG Americas Securities
New York
|
-$1.23M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.13M |
PRTK Hedge Fund Activity: Q1 2015 in Review
38 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q1 2015, worth a combined $292M — down 15% from $345M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PRTK positions and 9 closed out — a net gain of 1 holder — while 9 added to existing stakes and 9 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $6.24M. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $3.79M sold.
- 38 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q1 2015, up from 37 in Q4 2014.
- Funds reported $292M of Paratek Pharmaceuticals, Inc. stock for Q1 2015, down 15% quarter-over-quarter.
- 10 funds opened new Paratek Pharmaceuticals, Inc. positions in Q1 2015 and 9 closed out, a net change of +1 holder.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q1 2015 was JP Morgan Chase, an estimated $6.24M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q1 2015 was D.E. Shaw & Co, an estimated $3.79M sold.
Based on aggregated 13F filings for Q1 2015.